Q-omics provides the consensus-scored MYO10 profile across patient tissues and cancer cell-line models. MYO10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MYO10 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, MYO10 RNA expression shows 19,084 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, HNSC, and THYM as cancer lineages where MYO10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO10 survival associations across molecular data types. MYO10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO10 RNA expression–survival associations across cancer types. High MYO10 expression shows unfavorable associations in CESC, MESO, SKCM, ACC and PAAD, but favorable associations in KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for MYO10 RNA expression.
This table summarizes MYO10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYO10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO10 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, BLCA, UCEC and STAD. The HNSC box plot shows higher MYO10 RNA expression in tumor versus normal tissue (log2 FC = +1.986, t-test p < 0.001).
This table shows molecular features associated with MYO10 in patient tissues and cancer cell lines. In patient samples, MYO10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BREAST.
